Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

A 45-year-old woman with autoimmune diseases experienced patchy hair loss due to alopecia areata, which has no cure but can be treated, with varying success.

The back of the scalp has more nerve fibers than the front, which may explain why some people feel more sensitivity there.

BMP signaling controls hair growth and skin color.

A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.

Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.

Certain immune cells in the skin release a protein that stops hair growth by keeping hair stem cells inactive.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

A gene variant increases the risk of a type of hair loss by affecting hair protein production.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Hemp seed biomaterials may reduce hair loss and improve hair growth.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Oral tofacitinib successfully treated total body hair loss in one patient.

Natural products show promise for new hair loss treatments.

The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.

New genetic discoveries may lead to better treatments for alopecia areata.